

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



吉林省輝南長龍生化藥業股份有限公司

Jilin Province Huinan Changlong Bio-pharmacy Company Limited

(a joint stock limited company incorporated in the People's Republic of China)

(Stock Code: 8049)

ANNOUNCEMENT

(1) WITHDRAWAL OF ORIGINAL ORDINARY RESOLUTION NO. 10 AND ADDITIONAL RESOLUTION TO BE PROPOSED AT THE AGM; AND (2) REVISED NOTICE OF AGM AND REVISED PROXY FORM

References are made to the announcement, the notice of the annual general meeting (the “**Original Notice**”) and the form of proxy (the “**Original Proxy Form**”) of Jilin Province Huinan Changlong Bio-pharmacy Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 24 April 2026 in relation to, among other things, the proposed appointment of Mr. Zhang Biao as a supervisor of the Company (i.e. Ordinary Resolution No. 10 in the Original Notice). Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Original Notice.

WITHDRAWAL OF ORIGINAL ORDINARY RESOLUTION NO. 10 AND ADDITIONAL RESOLUTION TO BE PROPOSED AT THE AGM

As disclosed in the Original Notice, Mr. Zhang Biao was proposed to be nominated as a supervisor of the Company, subject to the approval of the shareholders of the Company (the “**Shareholder(s)**”) at the AGM.

Subsequent to the publication of the Original Notice and the Original Proxy Form, since Mr. Zhang Biao has decided to withdraw his candidacy for the nomination as a supervisor of the ninth session of the supervisory committee of the Company (the “**Supervisory Committee**”), the original Ordinary Resolution No. 10 in respect of the election of Mr. Zhang Biao as a supervisor of the Company as set out in the Original Notice and the Original Proxy Form is no longer applicable and will not be put forward for consideration and approval by the Shareholders at the AGM.

Mr. Zhang Biao has confirmed that he has no disagreement with the Board, and there are no other matters relating to his withdrawal that need to be brought to the attention of the Shareholders or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Proposed election and appointment of new supervisor

As proposed by the Supervisory Committee, the Board has resolved to nominate Ms. Yang Yang (“**Ms. Yang**”) as a candidate for supervisor of the ninth session of the Supervisory Committee. Such appointment is subject to the approval of the Shareholders at the AGM.

The biographical details of Ms. Yang are set out below:

Ms. Yang Yang (楊洋), aged 44, holds a bachelor’s degree. She graduated from the Tonghua Medical College of Jilin University majoring in Pharmacy. Since 2017, she has been working at the Company and currently serves as the Deputy Minister of the Technology Department. Ms. Yang has been deeply engaged in pharmaceutical technology research and development, and production process optimisation. She has a profound professional foundation, is familiar with pharmaceutical GMP specifications and industry regulatory rules, possesses strong principles, upright professional ethics, an outstanding sense of responsibility, and excellent risk control capabilities.

Save as disclosed above, as at the date of this announcement, Ms. Yang (i) has not held any directorships in any public listed companies in Hong Kong or overseas in the past three years; (ii) does not have any relationship with any directors, supervisors, senior management, substantial or controlling shareholders of the Company; (iii) does not hold any other position with the Company and other members of the Group; (iv) does not hold any other major appointments and professional qualifications; and (v) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

Subject to the Shareholders’ approval at the AGM, the Company will enter into a service contract with Ms. Yang for a term of three years, and her remuneration will be determined by the Board with the authorisation of the general meeting based on her duties and responsibilities. There is no other information relating to Ms. Yang that is required to be disclosed pursuant to Rule 17.50(2) of the Rules Governing the Listing of Securities on GEM of the Stock Exchange (the “**GEM Listing Rules**”), nor are there any other matters concerning her nomination that need to be brought to the attention of the Shareholders.

REVISED NOTICE OF AGM AND REVISED PROXY FORM

The date, time, and venue of the AGM remain unchanged. A revised notice of the AGM and a revised proxy form (the “**Revised Proxy Form**”) containing the new Ordinary Resolution No. 10 regarding the appointment of Ms. Yang will be despatched to the Shareholders in due course.

If a Shareholder has already completed and returned the Original Proxy Form in accordance with the instructions printed thereon, the Original Proxy Form (if correctly completed and returned) will remain valid. If no Revised Proxy Form is returned to the Company, the proxy so appointed under the Original Proxy Form will be entitled to vote at his/her discretion or abstain from voting on all resolutions properly put to the AGM, including the new Ordinary Resolution No. 10. If a Shareholder returns the Revised Proxy Form not less than 24 hours before the time appointed for holding the AGM, the Revised Proxy Form (if correctly completed and returned) will revoke and supersede the Original Proxy Form previously returned and will be treated as the valid proxy form for the AGM.

By order of the Board
Jilin Province Huinan Changlong Bio-pharmacy Company Limited
Zhang Hong
Chairman

Jilin, the PRC, 13 May 2026

As at the date of this announcement, the Board comprises six executive directors, being Zhang Hong, Zhang Xiao Guang, Zhao Bao Gang, Wu Guo Wen, Zhang Yi and Xu Xiang Fu and three independent non-executive directors, being Gao Qi Pin, Bai Jun Gui and Tian Jie.

This announcement, for which the directors of the Company collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The directors of the Company, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respects and not misleading; (2) there are no other matters the omission of which would make any statement in this announcement misleading; and (3) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

This announcement will remain on the “Latest Listed Company Announcements” page on the Stock Exchange’s website at www.hkexnews.hk for at least 7 days from the date of its posting.